Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Western blot or qRT-PCR was used to analyze the effect of NEK2 on the phosphorylation levels of ERK and c-JUN in two GC cell lines (BGC823 and SGC7901) with NEK2 overexpression, and the expression of the downstream effector cyclin D1.
|
31249448 |
2019 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results provide new insights into the pathogenesis and development of GC and rationale for developing novel intervention strategies against GC by disruption of ERK/MAPK-cyclin D1/CDK4 signalling.
|
30714150 |
2019 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As cyclin D1 and vimentin play an oncogenic role in gastric cancer, CORO1C may exert its tumor-promoting activity through these proteins.
|
30974047 |
2019 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The recovered CCND1 expression counteracted the effects of miR-623 on GC cell proliferation, chemosensitivity, and 5-FU-induced apoptosis.
|
29495973 |
2018 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Utilizing MTT, clonogenic, flow cytometry, wound healing and Transwell invasion assays in addition to Western blotting, the present study demonstrated that the overexpression of T-cad suppressed GC cell growth and colony formation via cell cycle arrest at the G0/G1 phase via downregulating the expression of cyclin dependent kinase 4 and Cyclin D1.
|
29104635 |
2017 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Upregulation of miR-143 inhibited cell proliferation, invasion, S phase cell proportion and cell cycle related protein levels of Cyclin D1, CDK4 and CDK6 in GC.
|
28718369 |
2017 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study demonstrated that UCA1 as a critical regulator involved in GC proliferation and cell cycle progression by promoting cyclin D1 expression, which indicates that it may be clinically a potential therapeutic target in GC.
|
28569779 |
2017 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Significant Role of Cyclin D1 in the Synergistic Growth-inhibitory Effect of Combined Therapy of Vandetanib with 5-Fluorouracil for Gastric Cancer.
|
27798882 |
2016 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
When stratifying by the type, Sex and H. pylori infection in dominant model, Interestingly, we found the opposite result in Male (AA + GA vs. GG: OR=0.5, 95% CI=0.33-0.76, P=0.001), there were no association between CCND1 G870A polymorphism and GC risk in any other subgroup.
|
27623072 |
2016 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The Kaplan-Meier method and cox proportional hazards model were used to analyze the relationship of HOXA1 and cyclin D1 expression with GC clinical outcomes.
|
26791264 |
2016 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further mechanism study indicated that CCND1 was a direct target of miR-193b in GC.
|
27071318 |
2016 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer.
|
25649416 |
2015 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HIF2α is associated with poor prognosis and affects the expression levels of survivin and cyclin D1 in gastric carcinoma.
|
25338835 |
2015 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Overall, 78% of GC cases harbored one clinically relevant GA or more, with the most frequent alterations being found in TP53 (50%), ARID1A (24%), KRAS (16%), CDH1 (15%), CDKN2A (14%), CCND1 (9.5%), ERBB2 (8.5%), PIK3CA (8.6%), MLL2 (6.9%), FGFR2 (6.0%), and MET (6.0%).
|
25882375 |
2015 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Fz2 shRNA suppressed cell proliferation and motility of MKN45 and MKN74 cells, and downregulated cyclin D1 and MMP-9 expression in these GC cell lines.
|
25586465 |
2015 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our results demonstrated that miR-638 suppressed GC cell proliferation by targeting Sp2 with influence on the expression of cyclin D1.
|
24623314 |
2014 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Since overexpressed cyclin D1 is closely related to human gastric cancer progression, inhibition of cyclin D1 using specific targeting could be an effective treatment method of human gastric cancer.
|
24618206 |
2014 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This study aimed to investigate the correlation of RKIP, STAT3 and cyclin D1 expression in the tumorigenesis of gastric cancer.
|
25337233 |
2014 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There was no such association of CCND1 G1722C with gastric cancer.
|
25202078 |
2014 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, β-cryptoxanthin induced an accumulation of cells in the G1/G0 phase of the cell cycle (as detected by flow cytometry), which was in accordance with an increased expression of p21 and down regulations of cyclin D1 and cyclin E, detected by Western blot analysis, and β-cryptoxanthin increased the mRNA levels of retinoic acid receptor β (RARβ) with the treatment at 10 μM for 24 h. Collectively, the above findings suggest that β-cryptoxanthin could be therapeutic in the treatment of stomach cancer cell in vitro.
|
23194503 |
2013 |
Stomach Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lentivirus-mediated shRNA targeting of cyclin D1 enhances the chemosensitivity of human gastric cancer to 5-fluorouracil.
|
24100731 |
2013 |
Stomach Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that miR-9 suppresses the expression of cyclin D1 and Ets1 via the binding sites in their 3'-UTR, thus inhibiting the proliferation, invasion and metastasis of gastric cancer.
|
23383271 |
2013 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Genetic polymorphism of CCND1 is associated with CIHM status in gastric cancer, especially in the advanced stage, but is independent of clinico-pathological features.
|
20397048 |
2010 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CCND1 genotype distribution among the patients was significantly different from that among controls; AA (odds ratio (OR)=0.348, 95% CI: 0.163-0.742) and GA (OR=0.715, 95% CI: 0.506-1.012) genotypes were significantly lower in the gastric cancer patients than in the controls when subjects with the GG genotype served as the reference category.
|
18609126 |
2008 |
Stomach Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, our findings suggested that the G870A polymorphism of cyclin D1 was not associated with an increased risk for gastric cancer in this population, however, it may contribute to susceptibility to gastric cancer in men.
|
17447856 |
2007 |